Cover Image
市場調查報告書

子宮內膜癌:開發中產品分析

Endometrial Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229742
出版日期 內容資訊 英文 533 Pages
訂單完成後即時交付
價格
Back to Top
子宮內膜癌:開發中產品分析 Endometrial Cancer - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 533 Pages
簡介

所謂所謂子宮內膜癌是發病於子宮內膜的癌症,是最常見的子宮癌。造成子宮內膜癌的原因雖然尚未明朗,但一般認為與雌激素的數值上升有關。原因是雌激素也有促進子宮內膜發達的作用。主要的症狀有不正常出血(非經期出血,及停經後的少量出血),與40歲以後的陰道出血(期間極長且頻繁、症狀又嚴重)、下腹部疼痛、骨盆痙攣、停經後的白色/透明陰道分泌物等。

本報告提供全球各國治療子宮內膜癌所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

子宮內膜癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

子宮內膜癌:企業開發中的治療藥

子宮內膜癌:大學/機關研究中的治療藥

子宮內膜癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

子宮內膜癌:企業開發中的產品

子宮內膜癌:大學/機關研究中的產品

子宮內膜癌治療藥的開發企業

  • Ability Pharmaceuticals, S.L.
  • Advenchen Laboratories, LLC
  • Aeterna Zentaris Inc.
  • Arno Therapeutics, Inc.
  • ArQule, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • BeiGene, Ltd.
  • BioNTech AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cellceutix Corporation
  • Critical Outcome Technologies Inc.
  • Eisai
  • Eli Lilly and Company
  • Esperance Pharmaceuticals, Inc.
  • Exelixis, Inc.
  • Galena Biopharma, Inc.
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Gradalis Inc.
  • Horizon Pharma Plc
  • ImmunoGen, Inc.
  • Incyte Corporation
  • Karyopharm Therapeutics, Inc.
  • Medivation, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • OncoHoldings, Inc.
  • 大塚集團
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Pharmsynthez
  • Pivot Pharmaceuticals Inc
  • Puma Biotechnology, Inc.
  • Sanofi
  • Shenogen Pharma Group Ltd.
  • Synthon Holdings BV
  • Vertex Pharmaceuticals Incorporated
  • Vyriad

子宮內膜癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

子宮內膜癌:最近的開發平台趨勢

子宮內膜癌:暫停中的計劃

子宮內膜癌:開發中止的產品

子宮內膜癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9395IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Pipeline Review, H1 2017, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 37, 35, 1 and 15 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Endometrial Cancer - Overview
  • Endometrial Cancer - Therapeutics Development
  • Endometrial Cancer - Therapeutics Assessment
  • Endometrial Cancer - Companies Involved in Therapeutics Development
  • Endometrial Cancer - Drug Profiles
  • Endometrial Cancer - Dormant Projects
  • Endometrial Cancer - Discontinued Products
  • Endometrial Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Endometrial Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Endometrial Cancer - Pipeline by AbbVie Inc, H1 2017
  • Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2017
  • Endometrial Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Endometrial Cancer - Pipeline by Aeterna Zentaris Inc, H1 2017
  • Endometrial Cancer - Pipeline by ArQule Inc, H1 2017
  • Endometrial Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
  • Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2017
  • Endometrial Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Bayer AG, H1 2017
  • Endometrial Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
  • Endometrial Cancer - Pipeline by BioNTech AG, H1 2017
  • Endometrial Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Endometrial Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Cellceutix Corp, H1 2017
  • Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Endometrial Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
  • Endometrial Cancer - Pipeline by Eisai Co Ltd, H1 2017
  • Endometrial Cancer - Pipeline by Eli Lilly and Company, H1 2017
  • Endometrial Cancer - Pipeline by Endocyte Inc, H1 2017
  • Endometrial Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Exelixis Inc, H1 2017
  • Endometrial Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Endometrial Cancer - Pipeline by Galena Biopharma Inc, H1 2017
  • Endometrial Cancer - Pipeline by GamaMabs Pharma SA, H1 2017
  • Endometrial Cancer - Pipeline by Genmab A/S, H1 2017
  • Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Endometrial Cancer - Pipeline by Glycotope GmbH, H1 2017
  • Endometrial Cancer - Pipeline by Gradalis Inc, H1 2017
  • Endometrial Cancer - Pipeline by Horizon Pharma Plc, H1 2017
  • Endometrial Cancer - Pipeline by Immunocore Ltd, H1 2017
  • Endometrial Cancer - Pipeline by ImmunoGen Inc, H1 2017
  • Endometrial Cancer - Pipeline by Immunomedics Inc, H1 2017
  • Endometrial Cancer - Pipeline by Incyte Corp, H1 2017
  • Endometrial Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Endometrial Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
  • Endometrial Cancer - Pipeline by MedImmune LLC, H1 2017
  • Endometrial Cancer - Pipeline by Merck & Co Inc, H1 2017
  • Endometrial Cancer - Pipeline by Merck KGaA, H1 2017
  • Endometrial Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Merus NV, H1 2017
  • Endometrial Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Novartis AG, H1 2017
  • Endometrial Cancer - Pipeline by Pfizer Inc, H1 2017
  • Endometrial Cancer - Pipeline by Pharma Mar SA, H1 2017
  • Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Puma Biotechnology Inc, H1 2017
  • Endometrial Cancer - Pipeline by Sanofi, H1 2017
  • Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd, H1 2017
  • Endometrial Cancer - Pipeline by Sigma-Tau SpA, H1 2017
  • Endometrial Cancer - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Synthon Holdings BV, H1 2017
  • Endometrial Cancer - Pipeline by Tesaro Inc, H1 2017
  • Endometrial Cancer - Dormant Projects, H1 2017
  • Endometrial Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Endometrial Cancer - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Endometrial Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top